Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 34 studies | 42% ± 16% | |
fibroblast | 28 studies | 34% ± 13% | |
oligodendrocyte precursor cell | 14 studies | 31% ± 12% | |
astrocyte | 13 studies | 28% ± 16% | |
pericyte | 13 studies | 31% ± 15% | |
endothelial cell of lymphatic vessel | 12 studies | 37% ± 15% | |
type I pneumocyte | 11 studies | 43% ± 20% | |
GABAergic neuron | 11 studies | 59% ± 22% | |
glutamatergic neuron | 11 studies | 56% ± 24% | |
smooth muscle cell | 11 studies | 34% ± 14% | |
connective tissue cell | 10 studies | 30% ± 11% | |
endothelial cell of artery | 10 studies | 27% ± 12% | |
adipocyte | 10 studies | 38% ± 11% | |
epithelial cell | 9 studies | 45% ± 17% | |
capillary endothelial cell | 8 studies | 27% ± 16% | |
club cell | 7 studies | 30% ± 13% | |
macrophage | 7 studies | 31% ± 11% | |
cardiac muscle cell | 7 studies | 65% ± 26% | |
vein endothelial cell | 7 studies | 28% ± 16% | |
T cell | 6 studies | 32% ± 9% | |
neuron | 6 studies | 39% ± 18% | |
interneuron | 6 studies | 63% ± 20% | |
retinal ganglion cell | 6 studies | 62% ± 17% | |
amacrine cell | 6 studies | 40% ± 15% | |
myofibroblast cell | 6 studies | 27% ± 16% | |
type II pneumocyte | 6 studies | 47% ± 9% | |
basal cell | 6 studies | 28% ± 11% | |
microglial cell | 5 studies | 42% ± 24% | |
mucus secreting cell | 5 studies | 37% ± 5% | |
endothelial cell of vascular tree | 5 studies | 35% ± 18% | |
regulatory T cell | 5 studies | 27% ± 10% | |
enteroendocrine cell | 5 studies | 55% ± 23% | |
pancreatic A cell | 4 studies | 71% ± 14% | |
type B pancreatic cell | 4 studies | 63% ± 15% | |
granule cell | 4 studies | 52% ± 10% | |
CD8-positive, alpha-beta T cell | 4 studies | 24% ± 7% | |
mesothelial cell | 4 studies | 30% ± 11% | |
lymphocyte | 4 studies | 38% ± 14% | |
muscle cell | 4 studies | 38% ± 20% | |
respiratory goblet cell | 4 studies | 47% ± 11% | |
natural killer cell | 4 studies | 33% ± 10% | |
kidney loop of Henle epithelial cell | 4 studies | 23% ± 5% | |
secretory cell | 3 studies | 21% ± 7% | |
pancreatic D cell | 3 studies | 52% ± 21% | |
GABAergic interneuron | 3 studies | 64% ± 10% | |
progenitor cell | 3 studies | 45% ± 4% | |
serous secreting cell | 3 studies | 24% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 30% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 23% ± 6% | |
GABAergic amacrine cell | 3 studies | 55% ± 18% | |
glycinergic amacrine cell | 3 studies | 30% ± 11% | |
ependymal cell | 3 studies | 41% ± 11% | |
monocyte | 3 studies | 27% ± 8% | |
adventitial cell | 3 studies | 34% ± 5% | |
chondrocyte | 3 studies | 43% ± 18% | |
epithelial cell of proximal tubule | 3 studies | 24% ± 4% | |
podocyte | 3 studies | 48% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 19677.52 | 258 / 258 | 98% | 244.08 | 225 / 230 |
lung | 99% | 10497.20 | 571 / 578 | 96% | 68.03 | 1110 / 1155 |
kidney | 97% | 7954.18 | 86 / 89 | 96% | 104.91 | 865 / 901 |
breast | 100% | 11102.78 | 457 / 459 | 93% | 61.73 | 1040 / 1118 |
thymus | 100% | 11855.83 | 651 / 653 | 92% | 137.00 | 559 / 605 |
uterus | 100% | 12024.75 | 170 / 170 | 91% | 54.61 | 418 / 459 |
prostate | 95% | 8320.33 | 233 / 245 | 91% | 40.79 | 457 / 502 |
ovary | 99% | 12114.07 | 179 / 180 | 86% | 51.27 | 370 / 430 |
intestine | 93% | 10399.45 | 899 / 966 | 89% | 42.59 | 467 / 527 |
esophagus | 87% | 9763.36 | 1251 / 1445 | 93% | 43.68 | 170 / 183 |
brain | 80% | 6935.84 | 2115 / 2642 | 99% | 74.79 | 698 / 705 |
bladder | 100% | 9973.86 | 21 / 21 | 75% | 36.67 | 380 / 504 |
pancreas | 75% | 3761.11 | 246 / 328 | 95% | 100.53 | 169 / 178 |
stomach | 84% | 6212.86 | 303 / 359 | 85% | 37.86 | 243 / 286 |
skin | 90% | 10872.26 | 1630 / 1809 | 61% | 34.01 | 286 / 472 |
blood vessel | 100% | 39688.66 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 12226.60 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 82164.39 | 844 / 861 | 0% | 0 | 0 / 0 |
muscle | 98% | 10711.67 | 785 / 803 | 0% | 0 | 0 / 0 |
spleen | 90% | 4933.25 | 216 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 84% | 34.31 | 38 / 45 |
eye | 0% | 0 | 0 / 0 | 41% | 12.60 | 33 / 80 |
lymph node | 0% | 0 | 0 / 0 | 31% | 6.04 | 9 / 29 |
peripheral blood | 25% | 1361.69 | 235 / 929 | 0% | 0 | 0 / 0 |
liver | 2% | 63.97 | 4 / 226 | 17% | 5.91 | 67 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010043 | Biological process | response to zinc ion |
GO_0001519 | Biological process | peptide amidation |
GO_0062112 | Biological process | fatty acid primary amide biosynthetic process |
GO_0030667 | Cellular component | secretory granule membrane |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0004598 | Molecular function | peptidylamidoglycolate lyase activity |
GO_0005507 | Molecular function | copper ion binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0004504 | Molecular function | peptidylglycine monooxygenase activity |
GO_0005515 | Molecular function | protein binding |
GO_0031418 | Molecular function | L-ascorbic acid binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | PAM |
Protein name | Peptidylglycine alpha-amidating monooxygenase Peptidyl-glycine alpha-amidating monooxygenase (PAM) [Includes: Peptidylglycine alpha-hydroxylating monooxygenase (PHM) (EC 1.14.17.3); Peptidyl-alpha-hydroxyglycine alpha-amidating lyase (EC 4.3.2.5) (Peptidylamidoglycolate lyase) (PAL)] peptidylamidoglycolate lyase (EC 4.3.2.5) |
Synonyms | |
Description | FUNCTION: Bifunctional enzyme that catalyzes the post-translational modification of inactive peptidylglycine precursors to the corresponding bioactive alpha-amidated peptides, a terminal modification in biosynthesis of many neural and endocrine peptides . Alpha-amidation involves two sequential reactions, both of which are catalyzed by separate catalytic domains of the enzyme. The first step, catalyzed by peptidyl alpha-hydroxylating monooxygenase (PHM) domain, is the copper-, ascorbate-, and O2- dependent stereospecific hydroxylation (with S stereochemistry) at the alpha-carbon (C-alpha) of the C-terminal glycine of the peptidylglycine substrate . The second step, catalyzed by the peptidylglycine amidoglycolate lyase (PAL) domain, is the zinc-dependent cleavage of the N-C-alpha bond, producing the alpha-amidated peptide and glyoxylate . Similarly, catalyzes the two-step conversion of an N-fatty acylglycine to a primary fatty acid amide and glyoxylate (By similarity). . |
Accessions | A0A804HK31 ENST00000438793.8 [P19021-1] ENST00000512073.1 A0A804HKM7 A0A804HJJ2 ENST00000506006.1 ENST00000682972.1 F8W8D9 H0Y9I4 D6RAQ2 ENST00000511839.5 ENST00000684529.1 [P19021-5] ENST00000682407.1 [P19021-6] ENST00000509523.2 ENST00000345721.6 ENST00000505654.1 ENST00000379799.7 ENST00000455264.7 [P19021-3] A0A804HLJ2 ENST00000346918.7 [P19021-4] ENST00000348126.7 [P19021-2] D6RF09 A0A804HIQ0 D6RCD5 Q7KYY0 A0A8C8KD64 ENST00000684043.1 P19021 ENST00000509832.5 ENST00000510208.2 D6RG20 A0A804HKV8 ENST00000504456.1 D6R961 A0A804HI59 ENST00000510006.6 H7BYD9 ENST00000684379.1 ENST00000682024.1 D6RDU2 ENST00000511477.5 ENST00000504691.1 ENST00000682882.1 ENST00000304400.12 A0A804HLE0 |